Capstan Therapeutics Stock
HealthTechLooking to sell Capstan Therapeutics stock or options?
Capstan Therapeutics aims to enhance the potential of in vivo RNA-based therapies by utilizing its proprietary targeted delivery systems. The company employs targeted lipid nanoparticles to facilitate off-the-shelf immunotherapies, ensuring precise control over the dosage and activity of engineered cells. This approach allows researchers to develop groundbreaking products for treating oncology, fibrosis, and inflammation-related diseases.
Vida Ventures (Boston), RA Capital Management, Bristol-Myers Squibb Foundation, Finchley Healthcare Ventures, Spur Capital Partners, Johnson & Johnson Innovation - JLABS, Pfizer Ventures, Leaps by Bayer, Novartis Venture Fund, Sofinnova Investments, Forbion, OrbiMed, Mubadala Capital, Perceptive Advisors, Bristol-Myers Squibb, Eli Lilly and Company Foundation, Alexandria Venture Investments, Polaris Partners.